Resource impact statement

No significant resource impact is anticipated

NICE has recommended bempedoic acid with ezetimibe as an option for treating primary hypercholesterolaemia or mixed dyslipidaemia as an adjunct to diet if certain criteria are met.

We do not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £5 million per year (or £9,000 per 100,000 population).

This is because the technology is a further treatment option and the overall cost of treatment will be similar.

Bempedoic acid and 2 of the other treatment options have discounts that are commercial in confidence. It is the company’s responsibility to let relevant NHS organisations know details of the discounts.

This technology is commissioned by clinical commissioning groups. Providers are NHS hospital trusts and GPs.

This page was last updated: